Search alternatives:
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
16301
-
16302
Modeling three-dimensional diffusion from a single cell.
Published 2012“…We interrogate how the concentration of total sulfide (H<sub>2</sub>S+HS<sup>−</sup>) changes as a function of time and distance from the source cell with or without surrounding cells. …”
-
16303
-
16304
-
16305
STATc is a key regulator of the transcriptional response to hyperosmotic shock-0
Published 2011“…After starvation for 4 hours, untreated cells and cells treated for 5 min with 50, 100, 200 and 400 mM sorbitol were fixed with ice cold methanol, and then stained with a monoclonal antibody specific for actin, followed by the incubation with anti-mouse IgG antibody conjugated with Cy5. …”
-
16306
-
16307
-
16308
-
16309
-
16310
-
16311
-
16312
Examination of mitochondrial function and cell viability in <i>PLA2G6</i>-KD cells.
Published 2015“…(B) Expression levels of CCO are decreased in <i>PLA2G6</i>-KD cells compared with those of SH-SY5Y cells treated with negative control siRNA with statistical significance (*<i>p < 0</i>.…”
-
16313
Data_Sheet_1_Exploring organizational aspects that promote health-related preventive behavior: using the example of work-related SARS-CoV-2 infection control measures in Germany, A...
Published 2024“…A total of 16 items constitute the attitude scores toward oICM (5-point Likert scale). Via mixed-effect model, aspects associated with employees’ attitudes toward oICM were explored. …”
-
16314
Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
16315
Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
16316
Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
16317
Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
16318
Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
16319
-
16320
A binding mode landscape for disordered protein interactions.
Published 2020“…Context-dependent <b>disorder-to-order</b> binding is exemplified by the <b>polymorphic interactions</b> of the ribosomal S6 kinase 1 (RSK1, residues 697–703, <i>light blue dots</i>), which adopts different secondary structures upon binding to S100B, corresponding to autoinhibited and active forms (PDB:5csf, 5csi, 5csj [<a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007864#pcbi.1007864.ref023" target="_blank">23</a>]). …”